Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
StinkyBritchesBoy is working so hard this weekend that it betrays his June OPEX anxieties as if they were frenziedly agitated by an expectation that clinical data readout WILL quickly follow the swift closing of the $31 million bought deal. His prognosticating mumblings to himself from multiple devices & his fortunes invite their abrupt Clarence Beeks ending.
The AF tweet can be interpreted as indicating 15 sophisticated retail investors supplanted the hedge fund interests that had made them privy to the call & offering with their own financial objectives.
[Hiring Spree] It took nearly a month to finalize this deal Feurenstein 5.17.21 https://bit.ly/3irve2R Cel-Sci CEO Geert Kersten spoke privately with investors last week as part of a “non-deal roadshow” organized by Kingswood Capital Markets, an investment bank that has helped the drug maker raise money in the past.
I'd be really surprised if it took till the middle of june
Tweeting activity is not limited by SEC as long as the public knows which posts originate from company accounts.
Anyone suggesting the CEO cannot make social media posts immediately before the company releases data implies that he also cannot use his telephone, talk to his neighbor, etc.
Intratumoural administration & tumour tissue targeting of cancer immunotherapies https://go.nature.com/34Tr4sG
Immune-checkpoint inhibitors and chimeric antigen receptor (CAR) T cells are revolutionizing oncology and haematology practice. With these and other immunotherapies, however, systemic biodistribution raises safety issues, potentially requiring the use of suboptimal doses or even precluding their clinical development. Delivering or attracting immune cells or immunomodulatory factors directly to the tumour and/or draining lymph nodes might overcome these problems. Hence, intratumoural delivery and tumour tissue-targeted compounds are attractive options to increase the in situ bioavailability and, thus, the efficacy of immunotherapies. In mouse models, intratumoural administration of immunostimulatory monoclonal antibodies, pattern recognition receptor agonists, genetically engineered viruses, bacteria, cytokines or immune cells can exert powerful effects not only against the injected tumours but also often against uninjected lesions (abscopal or anenestic effects). Alternatively, or additionally, biotechnology strategies are being used to achieve higher functional concentrations of immune mediators in tumour tissues, either by targeting locally overexpressed moieties or engineering ‘unmaskable’ agents to be activated by elements enriched within tumour tissues. Clinical trials evaluating these strategies are ongoing, but their development faces issues relating to the administration methodology, pharmacokinetic parameters, pharmacodynamic end points, and immunobiological and clinical response assessments. Herein, we discuss these approaches in the context of their historical development and describe the current landscape of intratumoural or tumour tissue-targeted immunotherapies.
Practical tool use has become Exceedingly TOXIC, irrational, & broken cookie jar stupid.
Living Large in Miami using shareholder wallets
The PIPE by family offices raises significant questions about insider trading & naked short selling. Threshold Security List requirements allow up to 4 consecutive days of FTD before the security is flagged. This rule matches nearly precisely volume trading of $IQST.
It is doubtful that the institutional investors & Family Offices haves sold even 1/3rd of the common shares obtained from the PIPES. They are likely teasing the float with imbalances to amplify scare tactic shakedowns by their alter ego avatars that keep manipulated & greedily expectant control of share price. They are not required to file 13Gs until after 1 calendar year has elapsed
Will we learn to what extent Multikine affects the microbiome's ability to facilitate treatment effectiveness and what the signature protein markers of responsiveness were?
innocuous
Are they incentive stock options or non-qualified or bonus? Up to 3,600,000
non-qualified stock options were approved from 2020's Def 14 A.
Why has the compensation committee approved these allotments? Who is on the compensation committee?
Are these Form 4s the 3rd of 3 parts for the study milestone & completion stock awards?
And/Or are they being doled out solely because of the technicality of having reached the anticipated study completion date resulting from the fact that the Company is under no statutory or regulatory obligation to amend the anticipated study completion date?
Fiber Optics & 5G ? Latin America
Is the IBank brutally manipulating the share price to capture a predetermined amount of OS to advance the capital formation agenda it shares with the company? Last summer it took less than 2 weeks for $ALPP to uplist to QB. the fourth week of our uplisting wait ends tuesday, Will a new excuse for delays be announced then if too many shares continue to be held by laypeople?
Small volume pre-market hours stock price manipulation is being perpetrated by commenters on this messageboard. Do not allow sympathetic charity to lead you to mistakenly attribute credibility to any commenter who relies upon first person character & life experience descriptions to underpin their messaging. Everyone here is selfish & greedy, but some conceive of their needs as being zero sum & malice dependent.
The client is the CRO who subcontracted data lock analysis and creation of the CSR.
Some commenters on here & the other messageboards routinely post fact distorting narratives to advance the financial interests of their employers. They then tactically redouble these prescribed views & pedal an illusion of credibility by using multiple devices to skirt multiple id TOS prohibitions. (Sushifishman is the worst f--ing offender)
Cheap stock options place strict upward limits on the stock price when data results are released. Who benefits most by talking down the stock & option prices of CVM? In the same light, anyone talking up the value of intermediate & long range option contracts is most likely just employed to sell junk.
Are new hires Security, Maintenance, Administrative Assistants, Legal Assistants, Pandemic Med Service Tech, & Bioassay Development???? Extrapolated! Manufacturing facility expansion must have commanded some of the new hires! It seems probable that about half of the 11 new hires during the past 12 months are Multikine related.
You are wrong. I've been checking & counting job postings on a daily basis for the last two weeks. My counts never indicated a posting had been removed, changed, or added until Friday afternoon.
For information sensitive valuations, is Friday after the close of regular trading an unusual time to post a New Job Opening (Quality Control Technical Writer) & draw attention to the fact that a prior job opening (Bioassay Development Specialist) is no longer available?
Looks like they filled a position. Will have to check the internet archive later to verify which one it was.
Next Week? vs. Cash for Gold scream sushi & the other self-interested & longtime stock prognosticators on this board Many competitors reported failed trials during HN month. While it would have been sweetly poetic to have had CVM report Multikine as a cure for HN on the last day of the month, it was always unlikely. With that being said, if the Multikine drug trial had failed, there was no shame to be found in reporting in chorus with the competitors. As such, it seems multikine may very well have proven to be an effective treatment for HN (I can't wait to learn if its effectiveness derives from its cytokine ability to disrupt cancer's energy use for cell division & metastasis thus allowing cell suicide to finally complete in host cells thereby effectively wounding the cancer with breaches penetrable by various healthy immune cells & platelets)
Joe Manchin has already stated that he will not vote for the infrastructure package if the tax rate is changed to those numbers. I'd expect the capital gains tax increase to be lowered to 25% but include a broader base of $750.000 & allow an increased home sales exclusion for single persons up to $375,000 & $750,000 for married couples. Also, I'd the bet the top income tax bracket settles at just over 38%
If CVM is sold, its CEO & board members will be highly recruited for top tier corporate governance positions that would allow them to earn a second fortune.
Exercising options on the precipice of data readout would be an ACTUAL example of illegal insider trading (and also stupid because any buyout will include Cash Plus for those options)
Multikine, the MegaBlockBuster Head & Neck Cancer drug from Cel-Sci, is so close to data readout that the CEO is now declining interviews from friendly financial media.
I look forward to seeing a state of the art cgi animated diagnostic presentation of their findings.
Tumor microenviromental response to treatment is fascinating. Looking forward to learning what Cel-Sci has discovered about tumor secretions in response to its immunotherapy treatment (i.e., what are their enzymatic/protein properties? How are they agonistically effective in responding to the body's immune responders [T Cells, Neutrophils, B Cells, Scavenger Cells, Platelets, etc]?)
Arm flailing attention seeking by the CEO is quite unusual. Legally, he can do anything but communicate that he has data, knows its results, & unofficially shares them or the release date. If he makes it onto Forbes list, what are his philanthropic intentions?
A probable Stock Plus Cash buyout converts all options & spares C-suite executives of the expense & unnecessary price trifling . When giving serious thought to this form 4 episode, I am left to conclude that it is a bit of a running joke in the respected hallways along San Tomas.
There is no reason he could not exercise options at their set prices by selling fewer shares of the company's stock he already held when its price reached its post data readout peak. His reasons are irrelevant to the risk decision I've fully committed myself to here.
I used an aspirational example of noble merit that I thought was contextually frivolous given the expected immediacy of data readout
So it is 10k = $240,000 of love showered on his children & grandchildren (education???) ..I've finally seen the actual form 4.
His Senior Vice President of Regulatory Affairs salary is sufficient for any everyday whim of elite life & cumulative planning.....
It was 1000 shares 1k = $24,000 = PRESENTS ..He still has 63,108 = $1.5 million ( + options )
I had thought StockVader would have made an appearance by now.
In accordance with my wild assumption about the planned & approved use of a commonplace 120 calendar for data statistical analysis, negative results were most likely to be reported this afternoon and that outcome window is now closed.
I am uninterested in NWBO comparisons that are dependent upon the continuing unknowns of whether statistical analysis of the data from its clinical trial has been arranged & enacted.
On day 121 of post data lock analysis cel-sci listed an employment opening for a supervisor of Quality Control. Did this signal the beginning for the evaluation of statistical analysis by the company (its scientists & legal team included) for its formulation & drafting of its study results public disclosure?
The idea of a time indefinite contract between the CRO & its contracted independent statistical reviewers is unfathomable.
There really is no reason why CVM or Kersten should not know or have had input on CRO affiliated contract deadlines.
IF I were a CEO who had known to expect a substantial increase in workload & global business travel as a result company milestones, I would time such expectations to coincide with when I was freshest...
Or so I've gambled in continued anticipation of the research investment market efficiency importance of publishing & presentation to the American Society of Clinical Oncology.
I'd think that the 2500 smarttanks mentioned in the LOI are primarily intended for their installation & tech specialists whose input is essential to ensuring tech manual specificity.
Is the IOT SmartTank App field test more about established & standardized IOT reliability or about the chemical company determining finer details for service product marketing & giving their legal department time to codify necessary changes to service contracts?
I am inclined to expect April revenues to have a noticeable bump up solely in response to the "field tests".
Perspective: What is the over/under for revenue exceeding $5 million for the month of March?
How long can you hold your breath?